Paula Cramer

6.8k total citations
74 papers, 1.5k citations indexed

About

Paula Cramer is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Paula Cramer has authored 74 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Genetics, 50 papers in Pathology and Forensic Medicine and 26 papers in Immunology. Recurrent topics in Paula Cramer's work include Chronic Lymphocytic Leukemia Research (64 papers), Lymphoma Diagnosis and Treatment (50 papers) and Immunodeficiency and Autoimmune Disorders (25 papers). Paula Cramer is often cited by papers focused on Chronic Lymphocytic Leukemia Research (64 papers), Lymphoma Diagnosis and Treatment (50 papers) and Immunodeficiency and Autoimmune Disorders (25 papers). Paula Cramer collaborates with scholars based in Germany, United States and Canada. Paula Cramer's co-authors include Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer, Kirsten Fischer, Clemens‐Martin Wendtner, Jasmin Bahlo, Anna‐Maria Fink, Hartmut Döhner, Petra Langerbeins and Raymonde Busch and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Paula Cramer

70 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paula Cramer Germany 20 1.2k 1.1k 445 335 273 74 1.5k
Karim Maloum France 19 1.2k 1.0× 920 0.9× 612 1.4× 336 1.0× 205 0.8× 51 1.6k
Jacques‐Louis Binet France 12 1.3k 1.1× 1.1k 1.1× 684 1.5× 330 1.0× 277 1.0× 21 1.8k
Seema A. Bhat United States 15 644 0.5× 550 0.5× 236 0.5× 231 0.7× 223 0.8× 69 1.4k
Liana Gercheva Bulgaria 15 707 0.6× 417 0.4× 209 0.5× 765 2.3× 194 0.7× 46 1.3k
Kena C. Miller United States 18 636 0.5× 506 0.5× 213 0.5× 696 2.1× 468 1.7× 69 1.4k
James D’Rozario Australia 10 565 0.5× 399 0.4× 212 0.5× 259 0.8× 163 0.6× 25 872
Lorenzo Falchi United States 20 520 0.4× 707 0.7× 271 0.6× 257 0.8× 569 2.1× 113 1.3k
Francesc Cobo Spain 18 650 0.5× 573 0.5× 176 0.4× 352 1.1× 367 1.3× 38 1.2k
Vesselina Goranova‐Marinova Bulgaria 14 473 0.4× 351 0.3× 168 0.4× 686 2.0× 331 1.2× 44 1.1k
Joanna Góra‐Tybor Poland 18 733 0.6× 381 0.4× 164 0.4× 594 1.8× 218 0.8× 82 1.2k

Countries citing papers authored by Paula Cramer

Since Specialization
Citations

This map shows the geographic impact of Paula Cramer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paula Cramer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paula Cramer more than expected).

Fields of papers citing papers by Paula Cramer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paula Cramer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paula Cramer. The network helps show where Paula Cramer may publish in the future.

Co-authorship network of co-authors of Paula Cramer

This figure shows the co-authorship network connecting the top 25 collaborators of Paula Cramer. A scholar is included among the top collaborators of Paula Cramer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paula Cramer. Paula Cramer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Knoll, Maximilian, Deyan Y. Yosifov, Christof Schneider, et al.. (2024). Biallelic Deletion 13q in Chronic Lymphocytic Leukemia Treated with Targeted Agents. Blood. 144(Supplement 1). 4608–4608.
3.
Tresckow, Julia von, Sandra Robrecht, Ali Aldaoud, et al.. (2023). Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group. Annals of Hematology. 102(11). 3083–3090. 4 indexed citations
4.
Fürstenau, Moritz, Jonathan M. Weiss, Sandra Robrecht, et al.. (2022). Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax. Clinical Cancer Research. 28(19). 4203–4211. 17 indexed citations
5.
Schilhabel, Anke, Paula Cramer, Julia von Tresckow, et al.. (2022). CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis. Cancers. 14(19). 4917–4917. 3 indexed citations
6.
Al‐Sawaf, Othman, Sandra Robrecht, Jasmin Bahlo, et al.. (2020). Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 35(1). 169–176. 62 indexed citations
7.
Cramer, Paula, et al.. (2020). The impact of inpatient capsule endoscopy on the need for therapeutic interventions in patients with obscure gastrointestinal bleeding. Saudi Journal of Gastroenterology. 26(1). 53–53. 5 indexed citations
8.
Al‐Sawaf, Othman, Alexandra Bazeos, Sandra Robrecht, et al.. (2019). Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). American Journal of Hematology. 94(9). 1002–1006. 5 indexed citations
9.
Jong, Jan de, Paula Cramer, Fatih Demırkan, et al.. (2019). Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. Pharmaceutical Research. 36(7). 93–93. 3 indexed citations
10.
O’Brien, Susan, Peter Hillmen, Steven Coutré, et al.. (2018). Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 18(10). 648–657.e15. 63 indexed citations
11.
Cramer, Paula, et al.. (2017). The Effect of Prucalopride on Small Bowel Transit Time in Hospitalized Patients Undergoing Capsule Endoscopy. Canadian Journal of Gastroenterology and Hepatology. 2017. 1–7. 10 indexed citations
12.
Fraser, Graeme, Paula Cramer, Fatih Demırkan, et al.. (2016). IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY. Haematologica. 101. 150–151. 4 indexed citations
13.
Cramer, Paula, Petra Langerbeins, & Michael Hallek. (2016). Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia. The Cancer Journal. 22(1). 62–66. 4 indexed citations
14.
Maurer, Christian, Petra Langerbeins, Jasmin Bahlo, et al.. (2016). Effect of first-line treatment on second primary malignancies and Richter’s transformation in patients with CLL. Leukemia. 30(10). 2019–2025. 35 indexed citations
15.
Pflug, Natali, Sandra Kluth, Jörg Janne Vehreschild, et al.. (2016). Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. OncoImmunology. 5(6). e1150399–e1150399. 83 indexed citations
16.
Cramer, Paula, Michael Hallek, & Barbara Eichhorst. (2016). State-of-the-Art Treatment and Novel Agents in Chronic Lymphocytic Leukemia. Oncology Research and Treatment. 39(1-2). 25–32. 21 indexed citations
17.
Cramer, Paula, et al.. (2016). Low volume polyethylene glycol with ascorbic acid, sodium picosulfate-magnesium citrate, and clear liquid diet alone prior to small bowel capsule endoscopy. World Journal of Gastrointestinal Endoscopy. 8(11). 433–433. 7 indexed citations
18.
Eichhorst, Barbara, Paula Cramer, & Michael Hallek. (2016). Initial therapy of chronic lymphocytic leukemia. Seminars in Oncology. 43(2). 241–250. 11 indexed citations
19.
Goede, Valentin, Paula Cramer, R. Busch, et al.. (2014). Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 99(6). 1095–1100. 72 indexed citations
20.
Cramer, Paula & Michael Hallek. (2012). New therapeutic targets and treatment strategies. Nature Reviews Clinical Oncology. 9(2). 72–74. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karim Maloum Breakdown of academic impact, for papers by Jacques‐Louis Binet Breakdown of academic impact, for papers by Seema A. Bhat Breakdown of academic impact, for papers by Liana Gercheva Breakdown of academic impact, for papers by Kena C. Miller Breakdown of academic impact, for papers by James D’Rozario Breakdown of academic impact, for papers by Lorenzo Falchi Breakdown of academic impact, for papers by Francesc Cobo Breakdown of academic impact, for papers by Vesselina Goranova‐Marinova Breakdown of academic impact, for papers by Joanna Góra‐Tybor
Rankless by CCL
2026